AU2020359526B2 - Benzoxazinone compounds as KLK5/7 dual inhibitors - Google Patents

Benzoxazinone compounds as KLK5/7 dual inhibitors

Info

Publication number
AU2020359526B2
AU2020359526B2 AU2020359526A AU2020359526A AU2020359526B2 AU 2020359526 B2 AU2020359526 B2 AU 2020359526B2 AU 2020359526 A AU2020359526 A AU 2020359526A AU 2020359526 A AU2020359526 A AU 2020359526A AU 2020359526 B2 AU2020359526 B2 AU 2020359526B2
Authority
AU
Australia
Prior art keywords
compound
formula
pharmaceutically acceptable
ppm
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020359526A
Other languages
English (en)
Other versions
AU2020359526A1 (en
Inventor
Andreas Betz
Robert Zamboni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Skin Therapeutics Inc
Original Assignee
Molecular Skin Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Skin Therapeutics Inc filed Critical Molecular Skin Therapeutics Inc
Publication of AU2020359526A1 publication Critical patent/AU2020359526A1/en
Application granted granted Critical
Publication of AU2020359526B2 publication Critical patent/AU2020359526B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU2020359526A 2019-10-01 2020-09-30 Benzoxazinone compounds as KLK5/7 dual inhibitors Active AU2020359526B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962909006P 2019-10-01 2019-10-01
US62/909,006 2019-10-01
PCT/US2020/053369 WO2021067335A1 (en) 2019-10-01 2020-09-30 Benzoxazinone compounds as klk5/7 dual inhibitors

Publications (2)

Publication Number Publication Date
AU2020359526A1 AU2020359526A1 (en) 2022-04-21
AU2020359526B2 true AU2020359526B2 (en) 2026-07-16

Family

ID=75274622

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020359526A Active AU2020359526B2 (en) 2019-10-01 2020-09-30 Benzoxazinone compounds as KLK5/7 dual inhibitors

Country Status (13)

Country Link
US (2) US11643420B2 (enExample)
EP (1) EP4037687B1 (enExample)
JP (1) JP7854389B2 (enExample)
KR (1) KR102994600B1 (enExample)
CN (1) CN114615984B (enExample)
AU (1) AU2020359526B2 (enExample)
BR (1) BR112022005881A2 (enExample)
CA (1) CA3151626A1 (enExample)
ES (1) ES3053975T3 (enExample)
IL (1) IL291398B2 (enExample)
MX (1) MX2022003929A (enExample)
TW (1) TWI918610B (enExample)
WO (1) WO2021067335A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200040103A1 (en) 2018-03-14 2020-02-06 Genentech, Inc. Anti-klk5 antibodies and methods of use
AU2020349509A1 (en) 2019-09-18 2022-03-31 Genentech, Inc. Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
MX2022003929A (es) 2019-10-01 2022-06-14 Molecular Skin Therapeutics Inc Compuestos de benzoxazinona como inhibidores dobles de klk5/7.
TW202304890A (zh) * 2021-04-14 2023-02-01 美商百歐克斯製藥公司 Klk5雙環雜芳香族抑制劑

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980287A (en) * 1987-06-09 1990-12-25 Teijin Limited 4H-3,1-benzoxazin-4-one compounds and pharmaceutical compositions thereof for the inhibition of serine proteases
US20030187256A1 (en) * 1998-03-31 2003-10-02 Berryman Kent Alan Benoxazinones/benzothiazinones as serine protease inhibitors
US20170002021A1 (en) * 2014-01-23 2017-01-05 Sixera Pharma Ab Benzoxazinone derivatives for treatment of skin diseases

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
DE4134770A1 (de) 1991-10-22 1993-04-29 Basf Ag Koernige bleichaktivatorzusammensetzung
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2184851A1 (en) 1996-09-05 1998-03-06 Cheng Chung Wu Method of manufacturing a microweavable flatware article made of synthetic material, the article produced thereby and an ink-imprinted film component for use in making the flatware article
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CN101152185B (zh) 2003-06-06 2010-12-08 阿里克斯股份公司 杂环化合物作为scce抑制剂的用途
MX2022003929A (es) 2019-10-01 2022-06-14 Molecular Skin Therapeutics Inc Compuestos de benzoxazinona como inhibidores dobles de klk5/7.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980287A (en) * 1987-06-09 1990-12-25 Teijin Limited 4H-3,1-benzoxazin-4-one compounds and pharmaceutical compositions thereof for the inhibition of serine proteases
US20030187256A1 (en) * 1998-03-31 2003-10-02 Berryman Kent Alan Benoxazinones/benzothiazinones as serine protease inhibitors
US20170002021A1 (en) * 2014-01-23 2017-01-05 Sixera Pharma Ab Benzoxazinone derivatives for treatment of skin diseases

Also Published As

Publication number Publication date
TWI918610B (zh) 2026-03-21
MX2022003929A (es) 2022-06-14
TW202126631A (zh) 2021-07-16
IL291398B1 (en) 2025-01-01
US12281123B2 (en) 2025-04-22
IL291398A (en) 2022-05-01
ES3053975T3 (en) 2026-01-28
US20210101911A1 (en) 2021-04-08
KR102994600B1 (ko) 2026-07-22
US11643420B2 (en) 2023-05-09
US20240067658A1 (en) 2024-02-29
CN114615984A (zh) 2022-06-10
CA3151626A1 (en) 2021-04-08
EP4037687A4 (en) 2023-09-27
JP7854389B2 (ja) 2026-05-01
EP4037687A1 (en) 2022-08-10
AU2020359526A1 (en) 2022-04-21
KR20220091488A (ko) 2022-06-30
BR112022005881A2 (pt) 2022-06-21
WO2021067335A1 (en) 2021-04-08
JP2022551583A (ja) 2022-12-12
EP4037687B1 (en) 2025-10-29
IL291398B2 (en) 2025-05-01
CN114615984B (zh) 2025-02-07